KIT and non-small cell lung carcinoma: E.g. 2014 National Comprehensive Cancer Network (NCCN) Guideline Insights highlighted the important role of KIT or PDGFRA mutation status in treatment decisions of gastrointestinal stromal tumours with imatinib and/or sunitinib24; The antibody-drug conjugate trastuzumab emtansine has improved outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer compared with trastuzumab-based therapy, as demonstrated in phase III studies25; BRAF-positive non-small cell lung cancer (NSCLC) is sensitive to Dabrafenib.